| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Wells Fargo analyst Derek Archila maintains Soleno Therapeutics (NASDAQ:SLNO) with a Overweight and lowers the price target ...
Soleno Therapeutics (NASDAQ:SLNO) reported quarterly earnings of $0.47 per share which beat the analyst consensus estimate of $...